74 Participants Needed

Combination Therapy for Pancreatic Cancer

Recruiting at 51 trial locations
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a combination of therapies in patients with advanced pancreatic cancer. The treatment aims to kill cancer cells directly, boost the immune system, and stop cancer growth. It focuses on patients whose cancer has spread and may not respond to standard treatments.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, you cannot take certain medications like strong CYP3A4 inhibitors or inducers, and you should avoid live vaccines and systemic immunosuppressive medications before and during the trial.

What safety data exists for the combination therapy involving Anetumab Ravtansine, Gemcitabine, Ipilimumab, and Nivolumab?

Gemcitabine, when combined with other drugs like nab-paclitaxel, erlotinib, and capecitabine, has shown an acceptable safety profile in patients with advanced pancreatic cancer. Nivolumab combined with nab-paclitaxel and gemcitabine was also assessed for safety in advanced pancreatic cancer, indicating it is generally safe for human use.12345

How is the combination therapy for pancreatic cancer with Anetumab Ravtansine, Gemcitabine Hydrochloride, Ipilimumab, and Nivolumab different from other treatments?

This combination therapy is unique because it includes a mix of chemotherapy (Gemcitabine), targeted therapy (Anetumab Ravtansine), and immunotherapy (Ipilimumab and Nivolumab), which is not a standard approach for pancreatic cancer. While Gemcitabine is a common treatment, the addition of these other drugs aims to enhance the immune response and target cancer cells more effectively, offering a novel strategy compared to traditional chemotherapy alone.26789

What data supports the effectiveness of the drug combination therapy for pancreatic cancer?

Research shows that combining ipilimumab (an immune therapy) with gemcitabine (a chemotherapy drug) may help overcome resistance in pancreatic cancer, potentially improving treatment outcomes. Additionally, gemcitabine combined with other drugs like nab-paclitaxel has been shown to improve survival in patients with advanced pancreatic cancer compared to using gemcitabine alone.1011121314

Who Is on the Research Team?

Anna Spreafico | UHN Research

Anna Spreafico, MD PhD

Principal Investigator

University Health Network Princess Margaret Cancer Center LAO

Are You a Good Fit for This Trial?

This trial is for adults with advanced pancreatic cancer that has spread and can't be removed by surgery. Participants must have tried at least one treatment before, have tumors expressing a protein called mesothelin, and be in good physical condition (ECOG score 0-1). They should not have untreated brain metastases or certain infections like HIV or hepatitis B/C. Women who can bear children and men with partners of childbearing potential must use effective contraception.

Inclusion Criteria

Your albumin levels in the blood need to be at least 2.5 mg/dL or higher.
Your hemoglobin level is 9 grams per deciliter or higher.
My cancer has grown in an area previously treated with radiation, and the growth can be measured.
See 18 more

Exclusion Criteria

I have not had major surgery in the last 4 weeks.
I have a corneal condition or other eye issues as diagnosed by my eye doctor.
I am currently receiving or have received chemotherapy or biological therapy.
See 18 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive anetumab ravtansine with nivolumab, ipilimumab, or gemcitabine in cycles of 21 or 28 days for up to 17 cycles

Up to 17 cycles (approximately 12-16 months)
Visits every 21 or 28 days for treatment administration

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 100 days post treatment, then every 12 weeks
Follow-up every 8 weeks for up to 100 days, then every 12 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Anetumab Ravtansine
  • Gemcitabine Hydrochloride
  • Ipilimumab
  • Nivolumab
Trial Overview The study tests anetumab ravtansine combined with nivolumab, ipilimumab, or gemcitabine to see which works best against pancreatic cancer. Anetumab ravtansine targets cancer cells directly while the other drugs help the immune system fight the disease or stop tumor growth. The trial aims to find out the safest doses and how well these combinations work together.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Group I: Arm III (anetumab ravtansine, nivolumab, gemcitabine)Experimental Treatment5 Interventions
Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Patients also receive gemcitabine hydrochloride over 30-40 minutes on days 1 and 8. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a biopsy and collection of blood on study.
Group II: Arm II (anetumab ravtansine, nivolumab, ipilimumab)Experimental Treatment5 Interventions
Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Patients also receive ipilimumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of cycles 2-4. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a biopsy and collection of blood on study.
Group III: Arm I (anetumab ravtansine, nivolumab)Experimental Treatment4 Interventions
Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a biopsy and collection of blood on study.

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Cancer Institute (NCI)

Lead Sponsor

Trials
14,080
Recruited
41,180,000+

Published Research Related to This Trial

The combination of ipilimumab and gemcitabine was found to be safe and tolerable for treating advanced pancreatic ductal adenocarcinoma (PDAC), with a maximum tolerated dose established at ipilimumab 3 mg/kg and gemcitabine 1,000 mg/m2.
Despite the safety of the regimen, the overall response rate was only 14%, indicating that adding ipilimumab does not significantly enhance the effectiveness compared to gemcitabine alone in advanced PDAC.
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study.Kamath, SD., Kalyan, A., Kircher, S., et al.[2022]
A study of 5465 patients with advanced pancreatic cancer in Ontario showed that the introduction of new chemotherapy regimens, GEMNAB and FOLFIRINOX, significantly improved overall survival rates over time, with median survival increasing from 5.6 months to 7.6 months between 2008 and 2018.
FOLFIRINOX was found to provide better overall survival compared to GEMNAB, particularly in younger and healthier patients, while GEMNAB still showed improved survival compared to the older standard treatment, gemcitabine.
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.Raphael, MJ., Raskin, W., Habbous, S., et al.[2023]
Itacitinib, a selective JAK1 inhibitor, combined with nab-paclitaxel and gemcitabine, showed an acceptable safety profile and clinical activity in patients with advanced solid tumors, including pancreatic cancer, with a 24% overall response rate across various doses.
The study indicated that while itacitinib was tolerated at lower doses, treatment-related toxicities such as neutropenia and fatigue were common, leading to dose adjustments; however, the study was terminated early due to negative results from a related phase III trial.
A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors.Beatty, GL., Shahda, S., Beck, T., et al.[2022]

Citations

Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. [2022]
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer. [2023]
Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer. [2022]
Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line. [2020]
Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. [2022]
A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors. [2022]
Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice. [2022]
Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. [2022]
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. [2022]
11.United Statespubmed.ncbi.nlm.nih.gov
Recent updates on the role of chemotherapy in pancreatic cancer. [2022]
12.United Statespubmed.ncbi.nlm.nih.gov
Present and future treatment of pancreatic cancer. [2022]
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). [2022]
14.United Statespubmed.ncbi.nlm.nih.gov
Future directions in the treatment of pancreatic cancer. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security